Georgiamune, a Maryland-based biotechnology company focused on immunology, has licensed an experimental cancer treatment to Stemline Therapeutics, a subsidiary of Menarini Group, in an agreement valued at up to $1.1 billion.
Under the deal announced October 22, Stemline will pay $45 million upfront in exchange for exclusive global rights to develop and market GIM-621. Georgiamune describes the preclinical candidate as a potential first-in-class oral small-molecule treatment for many solid tumors.
Georgiamune CEO Samir Khleif said the agreement transfers responsibility for advancing GIM-621 to Menarini, whose international development and commercial infrastructure could help move the program forward. The arrangement will also allow Georgiamune to concentrate on its remaining immunotherapy candidates.
Khleif explained that Georgiamune’s research focuses on discovering previously unexplored mechanisms governing immune-cell activity and translating those findings into first-in-class treatments for cancer and autoimmune disorders. He noted that GIM-621 is one of several programs emerging from this research, alongside three other candidates already undergoing clinical evaluation.
The company raised $93 million in a Series B financing round last month. Its remaining clinical-stage portfolio comprises early-development programs, each designed to pursue a first-in-class therapeutic approach.
Among these candidates are GIM-531, a small-molecule regulatory T-cell (Treg) inhibitor, and GIM-122, a dual-function monoclonal antibody. Both are being developed for solid tumors. Georgiamune is also advancing GIM-407, a Treg activator intended for autoimmune diseases, including celiac disease, systemic lupus erythematosus, type 1 diabetes and inflammatory bowel disease. Its other research programs remain in discovery or preclinical development.
For Menarini, the agreement adds another experimental asset to Stemline’s oncology portfolio, which already includes three marketed medicines covering breast cancer, multiple myeloma and a rare blood cancer.
The company has repeatedly turned to external licensing arrangements to expand its oncology pipeline. Last year, Stemline entered into a deal worth up to $550 million with AI-driven drug discovery company Insilico Medicine, following an earlier licensing agreement between the same companies.
Menarini Group CEO Elcin Barker Ergun welcomed the partnership, highlighting Georgiamune’s expertise in immuno-oncology and the potential of GIM-621 as an oral treatment for several solid tumor types. She said the candidate complements Menarini’s existing portfolio and that the group’s established oncology development and commercialization capabilities could help accelerate its progress.
Georgiamune is a clinical-stage biotechnology company developing innovative, potentially first-in-class treatments for cancer and autoimmune disorders. Its research centers on reprogramming immune signaling pathways, with a particular emphasis on the mechanisms controlling T-cell activation, regulatory T-cell activity and immune system balance.
Menarini Group is an international pharmaceutical and diagnostics company generating approximately $5.5 billion in annual revenue and employing more than 17,000 people. Its portfolio addresses areas of significant unmet medical need, including oncology, cardiology, gastroenterology, respiratory medicine, infectious diseases, diabetes, inflammatory conditions and pain management. With 18 manufacturing facilities and nine research and development centers, the company distributes its products across 140 countries.
Stemline’s major focus is on bringing transformational oncology treatment to people. One of its major treatments is elacestrant, which focuses on postmenopausal women.
Stemline Signs Major Deal for a Preclinical Cancer Drug
Stemline Therapeutics, a wholly owned subsidiary of the Menarini Group, has signed an exclusive worldwide licensing and collaboration agreement with Georgiamune for GIM-621, an experimental oral immunotherapy being developed for potential use against multiple solid tumors. Announced on October 22, 2026, the agreement could be worth up to $1.1 billion, including milestone payments and royalties. The deal represents a significant investment in early-stage oncology research and strengthens Stemline’s efforts to expand its cancer treatment portfolio.
